Benefit and Cost of Elevidys QuestionedBut while some experts are bullish on approval, others have cited potential drawbacks and concerns about the gene therapy. David Rind, the chief medical officer of the Institute for Clinical and Economic Review (ICER), penned an article in JAMA last week in which he noted that Elevidys missed its primary efficacy endpoint in two studies but still netted approva
- Forums
- ASX - By Stock
- PER
- Ann: WHO selects proposed INN for ATL1102
PER
percheron therapeutics limited
Add to My Watchlist
0.00%
!
1.0¢

Ann: WHO selects proposed INN for ATL1102, page-12
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.87M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 1.0¢ | $5.924K | 592.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4056872 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 3764467 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4056872 | 0.010 |
6 | 5659202 | 0.009 |
4 | 1260267 | 0.008 |
5 | 2282854 | 0.007 |
2 | 3200000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 3764467 | 6 |
0.012 | 1439598 | 4 |
0.013 | 1033000 | 2 |
0.014 | 2367834 | 5 |
0.015 | 1500000 | 1 |
Last trade - 15.43pm 16/06/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |